for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
Andrew Sharabi, M.D., Ph.D. (ucsd)
Photo of Andrew Sharabi
Andrew Sharabi



The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC). Avelumab is considered experimental because it is not approved by the United States (U.S.) Food and Drug Administration (FDA) for the treatment of cancer. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies are made to recognize, target and bind to specific proteins on the cells that make up your tissues. Avelumab is designed to block the interaction between PD-1, a known immune checkpoint, and PD-L1. By blocking this interaction, the immune system may be stimulated, allowing it to more effectively recognize and attack the cancer. Stereotactic Body Radiation Therapy (SBRT) is a type of radiation that uses precise targeting to deliver a high dose of radiation to the tumor over a short period of time. A positioning cushion such as Vac-lok will be used during radiation treatment that is custom made. This custom mold forms to the contours of the subjects body to allow for proper positioning comfort and stability.

Official Title

Phase I/II Study of the Safety, Tolerability, and Efficacy of Stereotactic Body Radiation Therapy (SBRT) Combined With Concurrent and Adjuvant Avelumab for Definitive Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)


This is a single arm open label Phase I/II study that will consist of two parts. In Phase I, investigators will assess the safety and tolerability of SBRT combined with Avelumab. In Phase II, investigators will determine whether SBRT combined with Avelumab improves relapse free survival. Subjects with Stage I NSCLC who are not undergoing surgical resection will be candidates for enrollment. Subjects will receive definitive stereotactic body radiation (SBRT) in 4-5 fractions combined with concurrent and adjuvant Avelumab at 10mg/kg for a total of 6 cycles. Subjects will be evaluated for safety as measured by the occurrence of adverse events, serious adverse events, and laboratory abnormalities. Three blood draws will be obtained to analyze anti-tumor immune responses and immune correlates.


Early Stage Non-Small Cell Lung Cancer cancer Non-Small Cell Lung Cancer SBRT Avelumab Stereotactic Body Radiation Therapy radiation NSCLC PD-1 PD-L1 Immunotherapy Lung Lung Neoplasms Carcinoma, Non-Small-Cell Lung SBRT+Avelumab


You can join if…

Open to people ages 18 years and up

  • Tumor(s) to be treated is(are) ≤ 5.0 cm or ≤250 cm3
  • Stage I NSCLC and is deemed medically inoperable or refuses surgical resection.
  • Life expectancy ≥ 9 months.
  • Acceptable organ and marrow function

You CAN'T join if...

  • Prior organ transplantation, including allogeneic stem cell transplantation
  • Significant acute or chronic infections including:
  • Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Known history of HBV or HCV
  • Active autoimmune disease
  • Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
  • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
  • Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable
  • Current use of immunosuppressive medication, EXCEPT for the following:
  • intranasal, inhaled, topical steroids, or local steroid injection (eg, intra-articular injection)
  • Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent
  • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  • Cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication.
  • Known severe hypersensitivity reactions to monoclonal antibodies any history of anaphylaxis, or uncontrolled asthma
  • Pregnancy or lactation
  • Known alcohol or drug abuse
  • Prior radiotherapy to the treatment site(s).


  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • Sanford Health
    Sioux Falls South Dakota 57104 United States

Lead Scientist at UC Health

  • Andrew Sharabi, M.D., Ph.D. (ucsd)
    Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He sees patients at the La Jolla Moores Cancer Center and his specialties include Prostate (Genitourinary) and Head and Neck Cancers, as well as Skin Cancer and Thoracic Malignancies.


in progress, not accepting new patients
Start Date
Completion Date
Andrew Sharabi
Phase 1/2
Study Type
Last Updated